A phase Ib/II study evaluating Fruquintinib plus 5-Fluorouracil/Leucovorin (5FU/LV) beyond progression on Fruquintinib monotherapy in metastatic colorectal cancer
Ontology highlight
ABSTRACT: Interventions: experimental group:Fruquintinib plus 5-Fluorouracil /Leucovorin
Primary outcome(s): recommended phase 2 dose (RP2D);6-month overall survival rate
Study Design: Single arm
DISEASE(S): Metastatic Colorectal Cancer Beyond Progression On Fruquintinib Monotherapy
PROVIDER: 2693103 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA